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Abstract 
Objective: Breast cancer survivors (BCS) are at high risk for the development of obesity, type 2 diabetes mellitus, 
and metabolic syndrome. There is increasing interest in the association between depression and metabolic dysfunc-
tion, which is relevant in this population as depression is often present in the chronic phase of cancer recovery. Thus, 
the aim of this study was to evaluate metabolic risk in BCS with and without depression compared to non-cancer 
controls.
Methods: African American (46 %) and Caucasian (54 %) postmenopausal BCS (N = 28; age: 60 ± 2 years; 
mean ± SEM) were matched for race, age (±2 years), and BMI (±2 kg/m2) to non-cancer controls (N = 28). Center for 
Epidemiologic Studies Depression Scale (CES-D) >16 or antidepressant medication usage was used to classify depres-
sion. Metabolic status was defined by 2-hr glucose during an OGTT and classification of metabolic syndrome.
Results: Compared to non-cancer controls, BCS had similar 2-hr glucose, but higher fasting glucose and total cho-
lesterol, and were 2.5 times more likely to have metabolic syndrome (21 vs. 52 %)(P’s < 0.05). Conversely, HDL-C was 
16 % higher in BCS (P < 0.05). Forty three % of BCS were on antidepressants compared to 14 % in non-cancer controls, 
despite similar mean CES-D scores (6 ± 1). Depressed BCS (46 %) had a higher BMI, waist circumference, fasting glu-
cose, and more metabolic syndrome components than non-depressed BCS (P’s < 0.05).
Conclusions: BCS have a heightened prevalence of depression that may be associated with an increased prevalence 
of metabolic syndrome. These results support the need to monitor weight gain, depression, and the progression of 
metabolic abnormalities after cancer diagnosis and treatment. Further studies into the mechanistic link between 
depression and metabolic disease are necessary to identify strategies that can offset their impact on obesity and 
associated cardiovascular risk following a breast cancer diagnosis.
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Due to better breast cancer screening modalities and 
cancer treatment options [1], the number of breast can-
cer survivors (BCS) in the United States is expected to 
increase from ~3 million survivors in 2012 to 3.8 million 
by 2022 [2]. Although more women are surviving this dis-
ease, a higher prevalence of depressive symptoms exists 
among BCS compared to the general female population, 
often persisting more than 5  years after diagnosis [3]. 
BCS also are at high risk for the development of obesity 
and associated cardiovascular disease risk, including 
metabolic syndrome, type 2 diabetes mellitus (T2DM), 
and hypertension [4, 5]. Depression and heightened 
metabolic dysfunction in chronic cancer BCS are often 
attributed to cancer diagnosis and treatment side effects, 
including emotional distress, pain, sleep disturbances, 
and excessive adiposity [6, 7].
Depression may affect the ability to make positive life-
style changes and comply with medical therapy [8], while 
antidepressant treatment is associated with weight gain 
[9], possibly placing BCS at even greater metabolic risk. 
Indeed, a recent meta-analysis concluded that depression 
is associated with worse glycemic control, poor adher-
ence to medication and diet regimens, and a reduction 
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circumference and low high-density lipoprotein choles-
terol (HDL-C) also show associations with depression 
in subjects with an unknown cancer history [11]. Thus, 
determining the presence of depression in BCS may 
have implications for clinical care in the chronic phase of 
recovery.
The tendency for weight gain with aging places post-
menopausal women at increased risk for metabolic 
dysfunction [12]. In addition to abdominal obesity, sig-
nificant risk factors for breast cancer in postmenopau-
sal women are elevated fasting glucose, hypertension, 
hyperlipidemia [13], all components of the metabolic 
syndrome. Less is known about whether cancer survivor-
ship increases metabolic risk during long-term recovery. 
Only a few studies have matched postmenopausal BCS to 
postmenopausal non-cancer controls [4, 14, 15], finding 
that BCS are more likely to have metabolic abnormalities 
than age-matched women without prior breast cancer. 
However, several limitations are present in these studies, 
including differences in BMIs between cases and con-
trols and/or lack of consideration of differences in racial 
profiles between groups, which could affect interpret-
ability of the results. Thus, this study evaluated metabolic 
risk and depression in postmenopausal BCS compared 
to postmenopausal women without a prior diagnosis 
of breast cancer matched for age, race, and BMI. We 
hypothesized that women with previous breast cancer 
have worse depression scores and poorer metabolic pro-
files compared to women without a history of breast can-
cer, and that this difference is independent of age, race, 
and obesity. Further, we anticipate that BCS with depres-
sion will have greater metabolic dysfunction than BCS 
without depression.
Methods
Study design and sample selection
This cohort study was observational in nature. Groups 
were comprised of 28 postmenopausal BCS and 28 post-
menopausal women without prior breast cancer diagno-
sis matched for race, age (±2  years), and BMI (±2  kg/
m2). All women reported being sedentary (<30  min of 
structured exercise, two times per week) and weight 
stable (<2  kg weight change) over the prior six months. 
Women without a history of breast cancer were selected 
from a larger subset of individuals from a previously 
published manuscript [16]. BCS were recruited from the 
Baltimore area and had completed surgical treatment, 
radiation therapy, and/or chemotherapy at least 6 months 
prior to enrollment. All women signed University of 
Maryland Institutional Review Board approved informed 
consent forms. A medical history, physical examination, 
resting 12-lead electrocardiogram, and fasting blood 
profile were performed to determine current metabolic 
abnormalities.
Cardiorespiratory fitness
VO2 was measured by indirect calorimetry dur-
ing a graded exercise test on a treadmill as previously 
described [17]. VO2max was accepted as valid if two 
of the three following criteria were met: respiratory 
exchange ratio ≥1.0, maximum heart rate >90 % of age-
predicted maximum (220-age), or a plateau in VO2 
(<200  ml/min change). If such criteria were met, the 
highest level of VO2 was defined as VO2max.
Depression assessment
Risk for depression was measured with the Center for 
Epidemiologic Studies Depression Scale (CES-D). The 
CES-D is composed of 20 items and assesses risk for 
depression in the general population. A cut off of 16 was 
used to indicate “mild” depressive symptomatology [18]. 
Subjects were classified as having depression if they had a 
CES-D score >16 and/or were being treated with an anti-
depression medication.
Clinical parameters and laboratory procedures
Height, body weight, and waist and hip circumferences 
were measured using standardized protocols [19], and 
BMI (kg/m2) and waist to hip ratio (WHR) calculated. 
Blood pressure was measured on the non-affected can-
cer side for BCS and on the right side in the non-cancer 
controls after 10  min of resting on three occasions and 
averaged.
Blood was collected after a 12 h fast. Plasma triglycer-
ide and cholesterol levels were analyzed using enzymatic 
methods (UniCelDxC880i; Beckman Coulter, Inc., Brea, 
CA), HDL-C measured in the supernatant after precipi-
tation with dextran sulfate, and low-density lipoprotein 
cholesterol (LDL-C) calculated as LDL-C =  total cho-
lesterol- HDL-C -TG/5 [20]. A oral glucose tolerance 
test was performed, with glucose measured at fasting 
and every 30 min. for 2  h following the ingestion of 
75 g glucose load. Glucose was measured by the glucose 
oxidase method (2300-STAT Plus; YSI, Yellow Springs, 
OH) and insulin measured by radioimmunoassay 
(Linco Research Inc., St. Charles, MO) [21]. The pres-
ence of three or more of the following metabolic syn-
drome components were used to diagnose metabolic 
syndrome: central obesity (waist  >88  cm), impaired 
glucose metabolism (fasting glucose  >5.6  mmol/L), 
elevated blood pressure (>130/85  mmHg or antihy-
pertensive treatment), and dyslipidemia (triglyceride 
(TG)  >1.7  mmol/L, HDL-C  <1.3  mmol/L, or hypolipi-
demic treatment) [22].
Page 3 of 6Serra et al. Diabetol Metab Syndr  (2016) 8:44 
Statistical analyses
Data were analyzed using SPSS Version 20. Data were 
analyzed for normality using the Kolmogorov–Smirnov 
test. Mean ±  SEM were calculated for continuous vari-
ables and compared using Student’s t test after log 
transformation of variables (plasma triglycerides), as 
appropriate. Percentages were calculated for categorical 
variables (presence vs. absence of medication usage, met-
abolic syndrome, and depression) and compared using χ2 
tests. Pearson correlation coefficients were calculated to 
determine relationships between variables. All tests were 




The women were 46 % African American and 54 % Cau-
casian. BCS were an average of 94  ±  18 (range 9–384) 
months since diagnosis. Treatment was lumpectomy 
in 54  % and mastectomy in 57  %. Forty-three percent 
underwent chemotherapy alone, 46  % radiation therapy 
alone, and 11  % received both. At study entry, 25  % of 
BCS were taking an aromatase inhibitor, 12 % tamoxifen, 
and 63 % were not receiving hormone therapy. BCS were 
well matched to non-cancer controls with regard to age, 
BMI, waist circumference, and WHR, but VO2max was 
25 % higher in BCS (P < 0.05) (Table 1).
Elevated metabolic abnormalities and depression in breast 
cancer survivors (Table 2)
On average, BCS had slightly elevated fasting glu-
cose, with 9  % higher fasting glucose than non-cancer 
controls (P  <  0.05). BCS also had higher HDL choles-
terol (P  <  0.05), tended to have higher total cholesterol 
(P = 0.08), and 39 % more required a lipid lowering med-
ication (P  <  0.01). Diastolic and systolic blood pressure 
and hypertension medication usage was similar between 
groups. BCS were 2.5 times more likely to have metabolic 
syndrome (21 vs. 52  %; P  <  0.05), with blood pressure 
(64  %) and waist circumference (61  %) being the most 
prevalent component in BCS.
CES-D scores >16 were observed in ~14 % of non-cancer 
control and BCS subjects. Despite similar mean CES-D 
scores, three times more BCS were being treated with an 
antidepressant medication (P < 0.05; 58 % of BCS were on 
a selective serotonin reuptake inhibitor, 25 % on an atypi-
cal antidepressant, and 17  % on a tricyclic antidepres-
sant). Twenty-six  % of non-cancer controls and 46  % of 
BCS were classified as depressed (CES-D >16 and/or on 
an antidepressant) (P = NS).
Comparisons of metabolic abnormalities by depression 
status in breast cancer survivors
As anticipated, BCS classified with depression had 
higher mean CES-D scores than BCS without depres-
sion (4.1 ±  0.9 vs. 8.5 ±  2.0, P  <  0.05). Despite similar 
age, racial profiles, fitness levels, and time from cancer 
diagnosis (data not shown), BCS with depression also had 
a higher BMI, waist circumference, fasting glucose, and 
more metabolic syndrome components (P’s < 0.05; Fig. 1) 
than non-depressed BCS. Further, there was a trend 
for fasting insulin to be higher (P  =  0.07) and HDL-C 
(P =  0.09) to be lower in BCS with depression (Fig.  1). 
Blood pressure and all other lipid variables were similar 
between groups, including the usage of hypertension and 
lipid lowering medications (data not shown).
Table 1 Demographic characteristics of  non-cancer con-
trols and breast cancer survivors
Mean ± SEM
BMI body mass index; WHR waist to hip ratio





Age (years) 60 ± 2 60 ± 2
BMI (kg/m2) 32 ± 1 32 ± 1
Waist circumference (cm) 96 ± 3 93 ± 1
WHR 0.81 ± 0.01 0.79 ± 0.01
VO2 max (ml/kg/min) 18.8 ± 1.0 23.5 ± 1.5a
Table 2 Elevated metabolic abnormalities and depression 
in breast cancer survivors
Mean ± SEM
HDL-C high-density lipoprotein cholesterol; LDL-C low-density lipoprotein 
cholesterol; CES-D Center for Epidemiologic Studies Depression Scale
Different than control: a P = 0.08; b P < 0.05; c P < 0.01
Control N = 28 BCS N = 28
Systolic blood pressure (mmHg) 121 ± 3 122 ± 2
Diastolic blood pressure (mmHg) 68 ± 1 68 ± 1
Hypertension medication usage (%) 43 56
Fasting glucose (mmol/L) 5.2 ± 0.1 5.7 ± 0.2b
Fasting insulin (pmol/L) 86 ± 7 97 ± 15
HOMA-IR 3.3 ± 0.3 4.1 ± 0.6
2-hr glucose (mmol/L) 7.1 ± 0.4 6.6 ± 0.6
Cholesterol (mmol/L) 4.8 ± 0.1 5.2 ± 0.2a
Triglycerides (mmol/L) 1.2 ± 0.1 1.4 ± 0.1
HDL-C (mmol/L) 1.4 ± 0.1 1.7 ± 0.1b
LDL-C (mmol/L) 2.8 ± 0.1 2.9 ± 0.2
Lipid lowering medication usage (%) 11 50c
Metabolic syndrome components (#) 1.7 ± 0.2 2.4 ± 0.3b
CES-D 6 ± 1 6 ± 1
Antidepressant medication usage (%) 14 43b
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Discussion
While numerous studies have identified weight gain as a 
consequence of breast cancer treatment extending into 
the chronic phase of recovery [23, 24], fewer studies 
have examined the prevalence of metabolic dysfunction 
in BCS. Although studies have reported that postmeno-
pausal BCS have more metabolic abnormalities than 
non-cancer controls [4, 14], ours is the first to show that 
this is independent of age, race, and obesity. We find that 
fasting glucose is higher, with a trend for higher choles-
terol, in BCS compared to non-cancer controls. We also 
determined that BCS are more likely to be treated for 
depression than non-cancer controls and that BCS with 
depression have more metabolic abnormalities. Thus, 
understanding the consequences of breast cancer diag-
nosis and treatment on risk for depression and metabolic 
dysfunction may aid in medical monitoring to optimize 
health during the survivorship phase of cancer recovery.
The pathophysiological response linking depression 
and metabolic dysfunction is inconclusive with regard to 
causal factors. It is postulated that depression is associ-
ated with increased stress and activation of the hypotha-
lamic–pituitary–adrenal (HPA) axis, which is involved 
in the pathogenesis of central adiposity and metabolic 
syndrome [25]. Greater metabolic dysfunction is associ-
ated with higher proinflammatory cytokines [26], many 
of which are elevated in BCS [27, 28]. Conversely, there 
is evidence that many cancer treatments, including radia-
tion and chemotherapy may activate an immune response 
[29, 30], leading to dysregulation of the HPA axis and, 
ultimately, depression [31]. Further, development of 
central adiposity also increases secretion of endogenous 
steroid hormones in obese, postmenopausal women [32]. 
High levels of circulating estrogen and testosterone are 
associated with an increased risk of breast cancer in peri- 
and postmenopausal women [33, 34]. Although, we do 
not believe estrogen concentrations have been compared 
between BCS and non-cancer controls, no differences 
in hyperandrogenic status (testosterone concentra-
tions >1.2 ng/ml) were found between these groups pre-
viously, despite observed metabolic differences [15]. 
Studies, including ours, suggest that as many as 50–55 % 
of BCS are depressed [35–37], which is ~20–25 % more 
than that observed in postmenopausal women without 
a history of cancer [38]. Further, our results agree with 
previous reports [14, 39] that metabolic syndrome is 
prevalent in ~50 % of postmenopausal BCS. This is ~1.5 
higher than what is observed in postmenopausal women 
of comparable age and BMI in NHANES [40] and our 
postmenopausal non-cancer controls. The presence of 
metabolic abnormalities and depression following breast 
cancer diagnosis are associated with elevated cancer 
recurrence and mortality rates [39, 41, 42], highlighting 
the importance of understanding the mechanism linking 
depression and metabolic dysfunction in BCS.
Often the failure to recover after breast cancer treat-
ment (i.e. low quality of life persisting for years follow-
ing completion of cancer treatment [43]) is attributed to 
Fig. 1 Prevalence of obesity and metabolic profiles of breast cancer survivors with (n = 13) and without (n = 15) depression (*P < 0.05, #P = 0.07, 
‡P = 0.09)
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lifestyle choices, including low activity levels and subop-
timal nutrient intake. However, our results suggest that 
the metabolic abnormalities and depression observed 
in BCS may not be attributable to low cardiorespiratory 
fitness, as these risk factors were present even though a 
higher VO2max was observed in BCS than non-cancer 
controls. Despite this finding, many studies suggest that 
depressive symptoms and metabolic dysfunction improve 
with exercise in BCS [44–46].
This study is limited by a small sample size, which pre-
vented stratification by breast cancer treatments and 
the control of length of time post-cancer treatment. As 
there is evidence that breast cancer treatments, includ-
ing chemical variations in drugs used for chemotherapy, 
may have varying effects on metabolism [47], future 
studies should attempt to stratify by treatment. There is 
limited data available on the impact of duration of survi-
vorship on the observed relationships; however, there is 
evidence that subjective outcomes (i.e. quality of life and 
depression) remain lower than pre-diagnosis or may even 
continue to decline during the survivorship phase [3, 48]. 
The cause of this continued failure to recover is not elu-
cidated and may be influenced by factors other than the 
cancer diagnosis and treatment (i.e. financial and emo-
tional support) during the survivorship phase. Although 
the gold standard for depression evaluation is the use of 
a clinician rated interview technique, such as the Struc-
tured Clinical Interview for DSM-IV Axis I Disorders 
and the Hamilton Depression Rating Scale, these meth-
ods require substantial subject time and trained clinical 
interviewers [49]. Self-report questionnaires, such as the 
CES-D, have strong validity and reliability [50] and are 
less burdensome [51] when compared to interview tech-
niques. Further, because of the pilot nature of this study, 
body composition assessments of the BCS were limited to 
anthropometric measurements. While more sophisticated 
measures of body composition may provide additional 
insight as to the role of cancer survivorship on metabo-
lism, these tests can be expensive and often require radia-
tion exposure, which may decrease participant interest in 
and compliance to the study protocol. However, some of 
these limitations are balanced by our strong study design, 
where BCS were matched for age, race, and BMI to non-
cancer controls. BMI of the subjects spanned from normal 
weight to morbidly obese, while most studies examining 
metabolic dysfunction in BCS only includes those who are 
obese; thus, these findings may be more representative of 
the general BCS population.
In summary, our results support the need to monitor 
weight gain, depression, and the progression of meta-
bolic abnormalities during treatment and longitudinally 
in BCS, as their development may affect long-term sur-
vivorship. Further studies into the mechanistic links 
between depression and metabolism are necessary to 
identify strategies that can offset their impact on survi-
vorship following a breast cancer diagnosis.
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